This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

HNSCC afatinib clinical trials

Afatinib* is currently being investigated in Phase III trials of patients with head and neck squamous cell carcinoma (HNSCC), an area of focus in which there is a high unmet need for effective treatments.

The following table shows the clinical trials of afatinib in head and neck cancer; you can find links to further information on this site and published papers.

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information. Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.